BRIEF published on 12/11/2024 at 07:34, 1 year 9 months ago Evotec SE et Novo Nordisk lancent les projets LAB eN² pour la découverte de médicaments Evotec SE Découverte De Médicaments Novo Nordisk LAB EN² Maladies Cardiométaboliques
PRESS RELEASE published on 12/11/2024 at 07:29, 1 year 9 months ago Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk Evotec SE announces selection of first projects for LAB eN² drug discovery accelerator with Novo Nordisk, focusing on cardiometabolic diseases from academic institutions Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
BRIEF published on 11/29/2024 at 07:36, 1 year 10 months ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
BRIEF published on 11/29/2024 at 07:36, 1 year 10 months ago Evotec annonce le départ de son directeur opérationnel et une restructuration interne Changement De Direction Evotec Médicaments Départ Du COO Restructuration Interne
PRESS RELEASE published on 11/29/2024 at 07:31, 1 year 10 months ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 1 year 10 months ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
BRIEF published on 11/22/2024 at 17:00, 1 year 10 months ago Evotec SE commente le retrait de l'offre d'Halozyme Evotec SE Valeur Actionnariale Proposition D'acquisition Thérapeutique Halozyme Offre Sans Engagement
PRESS RELEASE published on 11/22/2024 at 16:55, 1 year 10 months ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 1 year 10 months ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
BRIEF published on 11/14/2024 at 22:56, 1 year 10 months ago Evotec SE répond à l'intérêt d'Halozyme Evotec SE Reprendre Thérapeutique Halozyme Manifestation D'intérêt 11 EUR Par Action
Published on 10/03/2026 at 02:35, 20 hours 5 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day 8 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 9 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 9 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 6 hours 54 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 22 hours 44 minutes ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 2 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 2 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 1 day 3 hours ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 17:45, 1 day 4 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 4 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 5 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 5 hours ago Aéroports de Paris SA - Calendrier financier 2027
